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ABSTRACT
Background and aims The aim of the present study
was to determine the population prevalence of occult
hepatitis B (OHB) infection and its clinical profile in
a highly endemic area of chronic hepatitis B virus
disease.
Methods OHB was first identified by individual sample
testing for hepatitis B surface antigen (HBsAg) followed
by nucleic acid testing (NAT) and vice versa for 3044
(cohort 1, stored sera from donation within 1 year) and
9990 (cohort 2, prospective study) blood donors,
respectively. OHB was confirmed meticulously by $2 out
of 3 tests with detectable hepatitis B virus (HBV) DNA
using a sensitive standardised assay. Detailed serology
and viral load in the serum and liver were studied.
Results The prevalence of OHB was 0.13% (4/3044) and
0.11% (11/9967) for cohort 1 and 2, respectively. In
cohort 2, 10 out of 11 OHB samples were positive for
anti-HBc (hepatitis B core antigen) antibody (all were
immunoglobulin G). Seven had detectable anti-HBs. The
serum HBV DNA levels were extremely low (highest
14.1 IU/ml). Of the six donors who underwent liver
biopsies, all had normal liver biochemistry, extremely low
liver HBV DNA (highest 6.21 copies/cell) and nearly
normal liver histology. For those with viral sequence
generation, none had the common HBsAg mutant G145R.
Conclusions The prevalence of OHB in a highly endemic
area of chronic HBV was very low, thus implying a low
impact on transfusion services. To implement universal
screening, the high cost of NAT should be taken into
account. OHB blood donors had very low HBV replication,
and normal liver biochemistry and histology, conferring
a favourable prognosis.
INTRODUCTION
The prevalence of chronic hepatitis B (CHB) which
affects 400 million people worldwide has been fully
documented.1 The highly endemic regions with
carrier rates of >8% include Asia and Africa.
However, there is a lack of systematic and popu-
lation studies in Asia on the prevalence of occult
hepatitis B (OHB) virus infection, defined as the
presence of hepatitis B virus (HBV) DNA in the sera
or livers in subjects who are negative for serum
hepatitis B surface antigen (HBsAg). The paucity of
population-based data on OHB may be due to two
main reasons. First, the entity OHB has gained
global attention only recently. Secondly, there is no
generally accepted assay of HBV DNA detection for
OHB in which serum HBV DNA levels are usually
extremely low (<200 IU/ml).2 3 However, studies
on the prevalence of OHB have many implications
for the blood transfusion services as the infectivity
of blood products from donors with OHB remains
Significance of this study
What is already known about this subject?
< Occult hepatitis B, because of its low HBV DNA
levels, is a notoriously difficult disease to study.
< Prevalence of occult hepatitis B varies greatly
among different countries.
< The accuracy of detection of occult hepatitis B
depends on the performance of tests.
< Occult hepatitis B blood donors may transmit
hepatitis B virus through blood transfusion.
What are the new findings?
< Even in a highly endemic area of chronic
hepatitis B, the prevalence of occult hepatitis
B is low.
< Screening for occult hepatitis B by HBsAg
testing followed by nucleic acid testing has the
same yield compared with first screening by
nucleic acid testing.
< Serum and liver HBV DNA levels in subjects
with occult hepatitis B are extremely low and
highly sensitive assays are required to diagnose
the disease.
< Subjects with occult hepatitis B have normal
liver biochemistries and liver histology.
How might it impact on clinical practice in the
foreseeable future?
< The finding of low prevalence of occult hepatitis
B in a highly endemic area of chronic hepatitis B
provides useful information for planning and
implementation of screening of this disease in
transfusion services.
< The finding of the present study provides
evidence that screening by HBsAg testing
followed by nucleic acid testing may be the
more cost-effective approach.
< Subjects with occult hepatitis B, because of the
low viral levels and nearly normal liver histology,
are expected to have a good long-term outcome.
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largely unknown. The prevalence documented in cohort studies
is usually <1%.4e7 Large population studies are required in order
to define the prevalence with higher confidence of accuracy.
In addition, the serology, virology (in serum and in the liver)
and histology of subjects with incidental identification of OHB
have not been studied in detail.
We carried out the present large population study in Hong
Kong (where 8% of the population has CHB) with the primary
aim of determining the prevalence of OHB in our general
population by using two different screening strategies. The
secondary aims were to examine the viral and disease status of
subjects with OHB.
PATIENTS AND METHODS
The present study was carried out in two stages with two
cohorts. The first stage (cohort 1) involved testing of 3044 stored
sera randomly selected by the Hong Kong Red Cross Transfusion
Service. These sera were from blood donors who donated blood
within 1 year of the start of the present study. The time of
donation of these samples was between 1 June 2005 and 31 May
2006. The samples were retrieved from all the 18 governorates of
Hong Kong. All donor sera were first tested negative for HBsAg
(Abbott PRISM, Abbott Laboratories, Abbott Park, Illinois,
USA), antibody to hepatitis C virus (HCV) and antibody to HIV.
These samples were then tested individually (not by pooling)
using the COBAS TaqScreen MPX (Roche Molecular Systems,
Branchburg, New Jersey, USA) test on the s201 system (Roche
Instrument Center, Rotkreuz, Switerland), a screening nucleic
acid testing (NAT) for HBV, HCV and HIV. The lower limit of
detection of this assay for HBV is 3.7 IU/ml with a 95% CI of 3.3
to 4.4 IU/ml. Initial positive samples were then quantified for
the HBV DNA levels by a standardised commercial HBV DNA
assay, Artus HBV RG test (QIAGEN, Hilden, Germany). When
used with the QIAamp DSP Virus Kit (QIAGEN) for HBV DNA
extraction, the Artus HBV RG test has a 95% lower limit of
detection of 3.8 IU/ml, with a linear range of detection of
between 1.1 and >43109 IU/ml. Since the serum HBV DNA
levels of occult HBV subjects were expected to be very low, in
order to minimise the chance of false-positive or false-negative
results, the Artus HBV test was performed three times on three
separate occasions in all the samples which tested positive by
NAT. Definite OHB was defined as two or more of the three runs
of assays showing detectable HBV DNA levels. Further sero-
logical tests including antibody to HBsAg (anti-HBs), and total
and immunoglobulin M (IgM) antibodies to hepatitis B core
antigen (anti-HBc) using the Elecsys 2010 system (Roche Diag-
nostics, Mannheim, Germany) were performed.
In the second prospective stage (cohort 2) started in January
2006, subjects were recruited on site during blood donation.
After obtaining written informed consent from the donors,
15 ml of blood were taken for serological tests (see below). The
donors were interviewed with a questionnaire which included
the following information: (1) personal history of previous
donations, HBV vaccination, known hepatitis B, C and other
liver diseases, jaundice, alcohol intake (>20 g/day), diabetes
mellitus, hypertension, long-term medication and intake of
traditional Chinese medications; and (2) family history of
hepatitis B carriage, liver cancer and other chronic liver diseases.
During the recruitment period from 1 January 2006 to 3 June
2008, a total of 9990 blood donors were recruited. The sera were
first tested by NAT using the s201 system mentioned above.
NAT-positive samples were then tested for HBsAg to diagnose
overt CHB. The remaining NAT-positive samples which were
HBsAg negative were tested for OHB. Definite OHB was defined
by two out of three positive HBV DNA tests (Artus HBV RG
test, QIAGEN) on samples negative for HBsAg with the same
criteria as mentioned above. Tests for anti-HBs and anti-HBc
(total and IgM) as described above were also performed.
Donors with OHB from cohort 2 were recalled. Liver
biochemistry was performed after a second written informed
consent. Liver biopsies were performed in subjects who
consented. Liver tissues were assessed for histology which was
graded according to the Ishak’s criteria.8 Total intrahepatic HBV
DNA and covalently closed circular (ccc) DNA were assayed by
real-time PCR, as described in previous studies.9 10 Briefly,
primers and FRET (fluorescence resonance energy transfer)
probes directed against the HBV surface region were used for
real-time PCR quantification of the total intrahepatic HBV DNA
in the Rotorgene 3000 Real-time Multiplex System (Corbett
Research, Australia). For cccDNA detection (lower limit of
detection 0.002 copies/cell), the extracted liver DNA was first
treated with Plasmid-safe DNase (Epicentre, Madison,
Wisconsin, USA), followed by real-time PCR using primers
spanning the incomplete region in the HBV relaxed circular
genome. Human genomic DNA content in the liver DNA extract
was measured by real-time PCR using the b-globulin primers
and probes in the LightCycler Control DNA Kit (Roche Applied
Science, Mannheim, Germany). HBsAg mutations at amino acid
145 (G145R) were determined by PCR sequencing, using primers
spanning the HBV surface gene at nucleotides 426e600 (HBsAg
amino acid residues 134e148). The HBV DNA was amplified by
semi-nested PCR, using the sense primer HBV406s (both first
and second rounds; 59-CTTCATCCTGCTGCTATGCCT-39) and
antisense primer HBV608a (first round; 59-AAAGCCCAGGAT-
GATGGGAT-39) or HBV600a (second round; 59-CCANGAT-
GATGGGATGGGAATAC-39). The 216 bp amplicons were then
sequenced bi-directionally by the second round primers. HBV
genotypes were determined by phylogenetic comparison of the
same HBV DNA surface gene amplicons with HBV viral refer-
ence sequences in GenBank.
Both stages of the study were approved by the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster.
Statistical analysis
The present study was descriptive in nature. We calculated the
prevalence of OHB in the study populations. Continuous vari-
ables were expressed as the mean with SD and range. Compar-
isons of the demographic data between different groups of
subjects were performed by Student t tests for continuous
variables and c2 tests for categorical variables. Two-tailed
p values of <0.05 were considered to be statistically significant.
RESULTS
In cohort 1 with 3044 HBsAg-negative donors (1525 males, 1519
females), the mean age was 33.1 years (SD 10.6, range
16.0e62.3). NAT by the s201 system identified 12 positive
samples (0.4%). Four samples had detectable HBV DNA by the
Artus HBV RG test (two had 2 out of 3 tests, two had 1 out of 2
tests (sample volume not adequate for the third run)). If the
latter two cases were also regarded as having OHB, the preva-
lence of OHB was 0.13% with a 95% CI of 0.036% to 0.336%.
The HBV DNA levels of these six runs were 1.10, 1.21, 1.70,
2.16, 2.47 and 19.40 IU/ml. Of the 12 NAT-positive samples, 10
with adequate volume for further anti-HBc testing, six were
positive for anti-HBc (all were negative for IgM anti-HBc) of
which two had OHB.
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For the prospective cohort 2, the demographics and the report
of the questionnaires of the 9990 donors recruited are listed in
table 1.
Figure 1 shows the multistep approach by which the donors
with OHB were identified. OHB was found in 11 donors with
detectable HBV DNA (three in all 3 runs, eight in 2 out of 3
runs). The prevalence of occult HBV was 0.11% (95% CI 0.055%
to 0.197%). There were another four donor samples with
detectable HBV DNA only in 1 out of 3 runs. They were
regarded as suspected OHB.
The demographics, serum viral markers and serum HBV DNA
levels of the 11 confirmed occult HBV donors are listed in table 2.
Of these, 10 donors had no family history of CHB; one donor was
not sure. All had no family history of hepatocellular carcinoma or
cirrhosis. Nine had given previous blood donations. Only two
were known to have had HBV vaccinations (six had not received
HBV vaccinations; three were not sure). When compared with
blood donorswithout hepatitis B (n¼9956) and donorswith CHB
(n¼23),OHBdonorswere significantly older than donorswithout
hepatitis B (mean age 39.9 years (SD 12.1; range 20.4e57) vs
31.5 years (SD 10; range 16e65.8), respectively, p¼0.005) and
donors with CHB (mean age 25.6 years (SD 7.7; range 18.3e49.0),
p¼0.003). Therewere no significant differences in the gender ratio
between the three groups (all p>0.05).
Ten of the 11 samples of these OHB donors were positive for
total anti-HBc but all were negative for anti-HBc IgM, indicating
that these donors were not in the window phase of acute
hepatitis B infection, when subjects are positive for HBV DNA
and have yet to develop circulatory antibodies to HBsAg.
Nine donors agreed to undergo further liver biochemical tests
and viral sequencing, and six consented to liver biopsies. All
these OHB donors had normal liver biochemistry, extremely low
serum and liver HBV DNA and nearly normal liver histology
(table 2). The HBV surface regions of all nine donor samples
were successfully sequenced. Three donors carried genotype B
HBVand six carried genotype C HBV. All nine showed wild-type
glycine at HBsAg amino acid 145, indicating the absence of
G145R mutations (the vaccine escape mutants).
DISCUSSION
The present study documented a population prevalence of OHB
of 0.13% and 0.11% from two large cohorts of blood donors in
Hong Kong, an endemic area for CHB with a prevalence rate of
8%. These figures should be highly accurate. First, in contrast to
some previous studies which adopted pooled sample testing
with a pool of 6e500 donor sera, our study tested single samples
individually. It has been shown that the sensitivity of identi-
fying OHB is 3e10 times lower in pool sample testing compared
with individual single sample testing.11 12 Secondly, in order to
reduce the chance of false-positive results due to contamination
or real-time PCR noise signals as well as to enhance the detec-
tion rate of the PCR test in the context of extremely low HBV
DNA levels, at least two out of three runs by Artus HBV RG test
had to be positive before the samples were regarded as positive
for OHB. Although it is sometimes difficult to distinguish
between occult chronic HBV infection and acute infection in the
window period, the fact that nearly all OHB samples were
positive for anti-HBc (all in IgG form) suggested that the
subjects did not have acute HBV infection during the window
period when the blood was donated. A Taiwan study has also
shown that all the identified HBV DNA-positive and HBsAg-
negative follow-up samples had OHB with low HBV DNA titres
and none was in the window period.13
Previous studies using in-house HBV DNA testing with
a smaller number of subjects reported a rate of 0.01e0.02% and
2e4% for OHB in non-endemic and endemic areas of CHB,
respectively.4 14e16 The present study indicates that the preva-
lence of OHB was in fact low even in an area of high endemicity
for HBV. This is in accordance with a recent Taiwan study
showing a prevalence of 0.11% by using commercial NAT.13
NAT screening has been implemented in some countries in
Europe, North America, Australia, Japan and southeast
Asia.17e21 The results of the present study may provide impor-
tant information for individual countries to consider whether
universal NAT screening should be adopted. The implementa-
tion of NAT screening should also take into account the risk of
transmission of HBV from OHB donor blood products to
recipients which was not assessed in the present study. The
estimated transmission rate of HBV from blood transfusion is 1
in 300 000 in general.22 23 This rate should be even lower in an
OHB population not suffering from acute HBV infection,
although the exact chance of HBV transmission from OHB
donors remains to be determined. There are a few case reports
documenting possible HBV transmission from OHB donor blood
products.24e26 A careful look-back study to determine the clin-
ical outcome of recipients receiving blood products from occult
HBV donors should be performed in the future.
Table 1 Demographics and report of questionnaires of the 9990 donors
No. of subjects 9990
M:F (%) 5550:4440 (55.6:44.4)
Mean age, years (SD, range) 31.5 (10.1, 16e65.8)
Report of questionnaires
Past personal history
Previous blood donation (yes: no: not sure) 7714: 2245: 31 (77.2: 22.5: 0.3%)
HBV vaccination (yes: no: not sure) 2657: 3502: 3831 (26.6: 35.1: 38.4%)
HBV infection (yes: no: not sure) 11: 9906: 73 (0.1: 99.2: 0.7%)
HCV infection (yes: no: not sure) 0: 9924: 66 (0: 99.3: 0.7%)
Jaundice (yes: no: not sure) 44: 9745: 201 (0.4: 97.5: 2%)
Significant alcohol intake (yes: no) 205: 9785 (2.1: 97.9%)
Diabetes mellitus (yes: no: not sure) 15: 9939: 36 (0.2: 99.5: 0.4%)
Hypertension (yes: no: not sure) 29: 9940: 21 (0.3: 99.5: 0.2%)
Long-term medication (yes: no) 117: 9873 (1.2: 98.8%)
Family history
HBV infection (yes: no: not sure) 727: 9039: 224 (7.3: 90.5: 2.2%)
Liver cancer (yes: no: not sure) 179: 9639: 172 (1.8: 96.5: 1.7%)
Chronic liver disease (yes: no: not sure) 372: 9377: 241 (3.7: 93.9: 2.4%)
F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male.
9,990 donors
84 NAT +ve
9,956 without overt CHB
9,906 NAT -ve
61 HBsAg -ve 23 HBsAg +ve
(all anti-HBc +ve)
11 HBV DNA +ve*
(anti-HBc +ve in 10)
50 HBV DNA -ve
* Incidence of occult HBV: 0.11%
Figure 1 Diagram showing the steps of tests to identify occult
hepatitis B donors (+ve, positive; ve, negative).
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We carried out the present study in two separate cohorts by
using two different strategies of screening for OHB. In the first
cohort with 3044 donors, all the samples were first tested nega-
tive for HBsAg before being subjected to NAT and finally by
sensitive HBV DNA assay. In the second prospective cohort with
9990 donors, the samples were first tested by NAT. NAT-positive
samples were then tested for HBsAg. For NAT-positive and
HBsAg-negative samples, HBV DNA assay was performed to
identify OHB. Both strategies yield very similar prevalence rates.
This suggests that initial screening by HBsAg followed by NAT
has the same yield of detection as with initial screening by NAT.
HBsAg testing followed by NAT is obviously cheaper. However,
a practical advantage of adopting the second strategy of initial
screening by NAT is that there will be a faster release of blood
products for use once the NAT is negative since the sensitivity of
NAT is superior to detection of HBsAg by enzyme immunoassay
(EIA).27 Another potential advantage of using initial NAT
screening is its ability to detect HBV in the presence of antigen-
ically modified HBsAg such as G145R mutants, which may give
rise to negative results in HBsAg detection assays.28 However, our
study revealed that none of the occult HBV carried this G145R
mutation, a finding consistent with other studies.29 30
Since the cost for universal NAT screening is high, anti-HBc
screening has been suggested as an alternative. The positivity
rate of isolated anti-HBc in the general population directly
correlates with the endemicity of CHB. It is estimated to be up
to 17% in areas of intermediate endemicity.31 In areas which are
highly endemic for HBV infection, such as Hong Kong, the
prevalence rate of anti-HBs positivity was as high as 40% before
the implementation of universal HBV vaccination.32 A majority
of these anti-HBs-positive subjects would also be positive for
anti-HBc. In light of the low prevalence rate of OHB observed in
the present study, a high proportion of blood donations may be
discarded from usage unnecessarily if isolated anti-HBc posi-
tivity is used for screening HBV.
In the 11 OHB donors identified in cohort 2, all had normal
liver biochemistry and nearly normal liver histology with no or
insignificant necroinflammation and fibrosis. Performing liver
biopsies on these subjects was to be more confirmatory of the
diagnosis of OHB as we could not completely rule out false-
positive HBV DNA results obtained by very sensitive assay. In
addition, there are no data on the possible liver injury and
intrahepatic virological status in these subjects. The serum HBV
DNA levels were very low, with the highest value of 14.1 IU/ml
(19.4 IU/ml in cohort 1). This is consistent with the very low or
undetectable total intrahepatic HBV DNA, indicating that HBV
inside the liver is replicating at an extremely low rate. It has
been shown that most patients with CHB with HBsAg sero-
clearance still have detectable total intrahepatic and cccDNA.9 33
In the present study, the undetectable cccDNA in the liver
tissues is likely to be related to the extremely low viral load. This
suggests a favourable long-term prognosis in donors with OHB.
However, there are still two main concerns for these OHB
donors despite the low level of viral replication. There is
a possibility of reactivation of the hepatitis B disease if these
OHB donors should require immunosuppressive therapy in the
future, especially in regimens containing rituximab.34 Also the
low viral load is still of a theoretical concern in transmitting
HBV. It has been shown that as few as 1e10 HBV particles can
infect chimpanzees.35
One limitation of the present study was that the prevalence
of OHB elucidated by the present study may not be totally
representative for the general population in Hong Kong since it
recruited blood donors who were relatively young (mean age of
31.5 years, table 1) and healthy.
In conclusion, with the prevalence of only 0.1% of the popu-
lation havingOHB in an endemic area of highHBVprevalence, the
impact on the transfusion services is expected to be low. Imple-
mentation of universal screening of OHB in blood transfusion
services should be determined with the consideration of both the
disease prevalence and the cost incurred by the programme.
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Editor’s quiz: GI snapshot
An unusual inflammation of the colon
A 27-year Caucasian man received an unrelated donor bone
marrow transplant for severe aplastic anaemia. Six weeks later
he was re-admitted to hospital with a febrile illness. He devel-
oped profuse non-bloody diarrhoea and cervical lymphadenop-
athy was detected. Blood tests showed pancytopenia and peak
concentrations of C-reactive protein 100 mg/l, alanine amino-
tranferase 357 U/l and alkaline phosphatase 197 U/l. Standard
stool microscopy and culture did not reveal any abnormalities
and tests for Clostridium difficile toxins a and b were negative.
Flexible sigmoidoscopy revealed the following appearances from
the rectum to the extent of the examination (figure 1).
QUESTION
What is the cause for this atypical colitis and how would you
treat it?
See page 1427 for the answer
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